Investment Thesis
Early-stage pharmaceutical company with exceptional 6573% revenue growth and fortress balance sheet ($37.5M cash, zero debt), but concerning data quality issues (impossible 336% gross margin), persistent operating losses, and typical pharma execution risks create uncertainty pending clarification of financial metrics.
Strengths
- Exceptional 6573% YoY revenue growth indicating successful commercialization or product approval
- Fortress balance sheet with $37.5M cash, zero long-term debt, and 4.64x current ratio providing operational runway
- Positive free cash flow ($3.0M) and operating cash flow despite net losses demonstrates efficient cash deployment
Risks
- Impossible gross margin (336%) suggests data quality issues, one-time gains, or accounting complexity requiring clarification
- Operating losses of $9.4M and -41.5% operating margin indicate company requires significant revenue scale to achieve profitability
- Pharmaceutical sector inherent risks including clinical failure, regulatory rejection, competitive dynamics, and long development timelines
Key Metrics to Watch
- Gross margin normalization and clarification of 336% calculation source
- Operating margin trajectory and cash burn rate sustainability with current revenue base
- Path to operating profitability and clinical pipeline advancement through regulatory milestones
Financial Metrics
Revenue
22.5M
Net Income
-9.9M
EPS (Diluted)
$-0.10
Free Cash Flow
3.0M
Total Assets
162.0M
Cash
37.5M
Profitability Ratios
Gross Margin
336.2%
Operating Margin
-41.5%
Net Margin
-43.8%
ROE
-9.7%
ROA
-6.1%
FCF Margin
13.3%
Balance Sheet & Liquidity
Current Ratio
4.64x
Quick Ratio
4.06x
Debt/Equity
0.00x
Debt/Assets
15.4%
Interest Coverage
-6.33x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:31:02.481942 |
Data as of: 2026-03-31 |
Powered by Claude AI